000			01765 a2200481 4500
005			20250517054112.0
264		0	_c20160419
008			201604s 0 0 eng d
022			_a1423-0259
024	7		_a10.1159/000439223 _2doi
040			_aNLM _beng _cNLM
100	1		_aPfau, Maximilian
245	0	0	_aClinical outcome after switching therapy from ranibizumab and/or bevacizumab to aflibercept in central retinal vein occlusion. _h[electronic resource]
260			_bOphthalmic research _c2015
300			_a150-6 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aAngiogenesis Inhibitors _xtherapeutic use
650	0	4	_aBevacizumab _xtherapeutic use
650	0	4	_aDrug Substitution
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aIntravitreal Injections
650	0	4	_aMacular Edema _xdrug therapy
650	0	4	_aMale
650	0	4	_aRanibizumab _xtherapeutic use
650	0	4	_aReceptors, Vascular Endothelial Growth Factor _xtherapeutic use
650	0	4	_aRecombinant Fusion Proteins _xtherapeutic use
650	0	4	_aRetina _xpathology
650	0	4	_aRetinal Vein Occlusion _xcomplications
650	0	4	_aRetrospective Studies
650	0	4	_aTomography, Optical Coherence
650	0	4	_aTreatment Outcome
650	0	4	_aVascular Endothelial Growth Factor A _xantagonists & inhibitors
650	0	4	_aVisual Acuity _xdrug effects
700	1		_aFassnacht-Riederle, Heidi
700	1		_aBecker, Matthias D
700	1		_aGraf, Nicole
700	1		_aMichels, Stephan
773	0		_tOphthalmic research _gvol. 54 _gno. 3 _gp. 150-6
856	4	0	_uhttps://doi.org/10.1159/000439223 _zAvailable from publisher's website
999			_c25302935 _d25302935